The pharmaceutical industry dished out £340.3 million last year to healthcare professionals and organisations, a new payment disclosure database has revealed.
News
60% response rate with Novartis’ rare blood cancer drug
A mid-stage trial assessing Novartis’ experimental rare blood cancer (midostaurin) has shown high response rates in patients with systemic mastocytosis.
Leukaemia drug shows promise in ovarian cancer
A drug approved for leukaemia has also shown promise in treating a specific type of ovarian cancer in a Cancer Research UK-funded study published in the journal Molecular Cancer Therapeutics.
BMS, PsiOxus to test new cancer combo
Bristol-Myers Squibb and England’s PsiOxus Therapeutics have announced a deal to work together on a new combination therapy targeting several different tumour types in late-stage cancer patients.
Merck, Moderna link in personalised cancer vaccines deal
Merck and Moderna Therapeutics have linked under a strategic collaboration and license agreement to develop and commercialise cancer vaccines based on novel messenger RNA.
Shire to re-file ADHD drug this year
Shire is now gearing up to re-file its attention-deficit hyperactivity drug SHP 465 in the US by the end of this year, on the back of new data further backing its safety and efficacy.
42% of public willing to pay more tax for NHS
Forty-two percent of the public are willing to pay more tax to support the NHS, as public sense of the financial crisis facing the service grows, suggest findings of the latest British Social Attitudes Survey by NatCen.
Fourth breakthrough designation for Janssen’s Imbruvica
Janssen’s Imbruvica has picked up a fourth breakthrough designation as well as Orphan status from US regulators as a treatment for chronic graft-versus-host-disease (cGVHD).
Internal and external recognition and career development for marketers
PharmaTimes Media invites marketers and teams to enter its prestigious Marketer of the Year competition, designed to benchmark talent within your organisation and across our industry.
Company news roundup – 27 June
The latest deals, launches and announcements across the industry
EU clears AstraZeneca’s new antibiotic
AstraZeneca’s Zavicefta has been approved for use in the European Union to treat patients with serious Gram-negative bacterial infections requiring hospitalisation.
Cambridge Uni spin-off raises £12m for cancer therapeutics
Cambridge University spin-off Storm Therapeutics has secured £12 million in series ‘A’ funding to advance its work on targeting enzymes that modify RNA to generate novel cancer therapeutics.
US clears Gilead’s pan-genotypic hepatitis C therapy
Gilead’s Sovaldi-based combination therapy for hepatitis C has been cleared for use by the US Food and Drug Administration to treat all six types of the virus, potentially eliminating the need for genotype testing.
Novartis picks up bispecific antibodies from Xencor
Novartis has signed a collaboration and licensing deal with California biotech Xencor for access to its bispecific antibody technology and rights to develop and commercialise two of the latter’s flagship experimental therapeutics.
Novel lung biopsy model could boost cancer diagnoses
Patients at Barnet Hospital are able to have small lung tumours diagnosed and cells destroyed in a single hospital visit without surgery, after the innovative 30-minute outpatient lung biopsy service was awarded the £100,000 Cancer Challenge Prize earlier this year.
